Lynk Pharma Reports Positive Phase III Results for Zemprocitinib in RA
January 12, 2026 | 11:32
Lynk Pharmaceuticals shares encouraging topline data from Phase III trials of Zemprocitinib, showing promise in treating rheumatoid arthritis patients effectively.
Mobile Version